16 Nov SIMPLAAFY Trial: Simpler Antithrombotic Regimens After WATCHMAN FLX Pro Left Atrial Appendage Closure
Health Notice: The aspirin-only and reduced-dose NOAC regimens discussed in this interview are investigational and are not part of the current device labeling. Antiplatelet and anticoagulant medications should only be prescribed, adjusted or stopped by your healthcare provider. Never change or stop blood-thinning medication on your own. This interview is for educational purposes and is not medical advice.
Editorial Notice: The interviewee is an employee of Boston Scientific, the manufacturer of the WATCHMAN FLX Pro device and the sponsor of the SIMPLAAFY trial. Products and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Dr. Brad Sutton, MD[/caption]
MedicalResearch.com Interview with:
Dr. Brad Sutton, M.D.
Chief Medical Officer, AF Solutions
Boston Scientific
Antithrombotic Therapy After Left Atrial Appendage Occlusion: The SIMPLAAFY Randomized Clinical Trial
MedicalResearch.com: What is the background for this study? Would you briefly explain what the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device is indicated for?
Response: The SIMPLAAFY randomized controlled trial is evaluating whether simplified antithrombotic regimens following implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device can reduce bleeding risk while providing effective protection against device-related blood clots in patients with non-valvular atrial fibrillation (NVAF). While dual antiplatelet therapy (DAPT) helps prevent clotting as the heart tissue heals over the device, it also carries a risk of bleeding. The trial is comparing the safety and efficacy of on-label DAPT with two investigational monotherapy regimens: aspirin alone for the 12-month duration of the trial or reduced-dose non-vitamin K antagonist oral anticoagulant (NOAC) for the first three months followed by aspirin only. The six-month results were presented at the 2026 TCT Conference and simultaneously published in JAMA.
The WATCHMAN FLX Pro LAAC Device is designed to reduce stroke risk by closing the left atrial appendage, where stroke-causing blood clots can form in patients with NVAF. It represents an alternative approach to long-term oral anticoagulation for eligible patients who are at increased risk of stroke, are suitable for anticoagulation therapy and have an appropriate reason to seek a non-drug alternative. Patients with NVAF who have undergone prior cardiac ablation may also be eligible without needing a separate rationale for avoiding long-term anticoagulation. The device also features HEMOCOAT™ Technology, designed to promote faster, more controlled healing after implantation.
Dr. Bell[/caption]
Dr. Jack Bell
Liverpool Heart and Chest Hospital
Liverpool, UK
MedicalResearch.com: What is the background for this study?
Response: Coronary computed tomography angiography (CCTA) is a non-invasive heart scan used in the first-line investigation of patients with suspected stable coronary artery disease (CAD). While CCTA clearly shows blockages in coronary arteries, it is limited in its ability to estimate reduced blood flow, which is necessary to diagnose angina.
An artificial intelligence-based tool (Heartflow) has been developed that analyses CCTA images and provides an estimate of blood flow: CT-derived fractional flow reserve (FFR-CT). The real-world, retrospective English FISH&CHIPS study demonstrated that including FFR-CT as a decision-making tool in the diagnosis of stable CAD reduces the number of subsequent invasive and non-invasive tests performed.
Whether FFR-CT could also be used prognostically, to predict future major cardiovascular events, was not fully understood. Previous studies have had small patient numbers, short follow-up and investigated combined cardiovascular outcomes. We performed an analysis on the national FISH&CHIPS population, which was large enough to determine if FFR-CT adds incremental value to traditional cardiovascular risk factors in predicting cardiovascular outcomes and death.
Prof. Lemesle[/caption]
Gilles Lemesle, M.D., Ph.D
Lille University Hospital, Lille, France